Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04047602 · ClinicalTrials.gov registry record · NA
Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A Prospective Pilot Study
A NA study, sponsored by Indiana University.
- Terminated
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT04047602 is a NA study that was terminated before completion, run by Indiana University. The registered enrollment target is 18 participants.
The verdict
NCT04047602, a NA study, was terminated before completion, sponsored by Indiana University.
- TERMINATED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study will evaluate the rate of radiation necrosis following treatment with immune checkpoint inhibitor (ICI) treatment and radiation therapy in subjects with metastatic brain cancer. Subjects will be treated with the standard of care immunotherapy followed by radiation therapy via stereotactic radiosurgery at a reduced dose.
Interventions
- RADIATION Reduced Dose SRS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-12-12 |
| Est. Completion | 2024-02-20 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04047602
The ClinicalTrials.gov registry entry for NCT04047602 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Reduced Dose SRS is the first listed.
NCT04047602 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04047602 about?
NCT04047602 is a clinical study titled "Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A Prospective Pilot Study". This study will evaluate the rate of radiation necrosis following treatment with immune checkpoint inhibitor (ICI) treatment and radiation therapy in subjects with metastatic brain cancer. Subjects will be treated with the standard of care immunotherapy followed by radiation therapy via stereotactic...
What is the current status of trial NCT04047602?
This trial is currently terminated. It is a NA study. The enrollment target is 18 participants. The study started on 2019-12-12. Estimated completion is 2024-02-20.
What interventions are being tested in trial NCT04047602?
The interventions under investigation include: Reduced Dose SRS (RADIATION).
Who is sponsoring clinical trial NCT04047602?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.